Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes

Simona Sica, Fabio Efficace, Franco Mandelli, Giuseppe Avvisati, Francesco Cottone, Felicetto Ferrara, Eros Di Bona, Giorgina Specchia, Massimo Breccia, Alessandro Levis, Olimpia Finizio, Maria Grazia Kropp, Giuseppe Fioritoni, Elisa Cerqui, Marco Vignetti, Sergio Amadori, Richard F. Schlenk, Uwe Platzbecker, Francesco Lo-Coco

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid (ATRA) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed, low- or intermediate-risk acute promyelocytic leukemia (APL). Here, we report health-related quality-of-life (HRQOL) results.
Original languageEnglish
Pages (from-to)3406-3412
Number of pages7
JournalJournal of Clinical Oncology
Volume32
DOIs
Publication statusPublished - 2014

Keywords

  • allogeneic

Fingerprint

Dive into the research topics of 'Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes'. Together they form a unique fingerprint.

Cite this